#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13166	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2024	639.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1402	1402	C	772	C	754	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23642	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3367	694.8	0	.	n	.	0	A20C	SNP	20	20	A	253	253	C	417	C,A	405,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23642	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3367	694.8	0	.	n	.	0	T695C	SNP	695	695	T	928	928	C	701	C	687	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23642	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3367	694.8	0	.	n	.	0	A1638G	SNP	1638	1638	A	1871	1871	G	808	G	792	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23642	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3367	694.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2204	2204	C	763	C,T,A	740,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23642	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3367	694.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2278	2278	A	758	A	741	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23642	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3367	694.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2830	2830	C	707	C	694	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1766	folP	855	855	100.0	folP.l15.c4.ctg.1	1696	103.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1089	1091	AGC	176;175;177	A;G,T;C	173;171,1;175	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5014	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3309	150.1	1	SNP	p	S91F	1	.	.	271	273	TTC	559	561	TTC	154;156;155	T;T;C	148;153;152	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5014	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3309	150.1	1	SNP	p	D95G	1	.	.	283	285	GGC	571	573	GGC	153;152;150	G;G;C	148;147;145	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5014	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3309	150.1	1	SNP	p	G95N	0	.	.	283	285	GGC	571	573	GGC	153;152;150	G;G;C	148;147;145	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1422	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1269	111.1	0	.	p	.	0	F184L	NONSYN	550	552	TTC	821	823	TTG	141;139;140	T;T;G,T	134;135;136,1	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1422	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1269	111.1	1	SNP	p	G45D	0	.	.	133	135	GGC	404	406	GGC	176;175;174	G;G;C	171;169;168	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	822	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1066	76.3	0	.	n	.	0	A197.	DEL	197	197	A	638	638	A	189	A	186	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4320	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2999	142.4	1	SNP	p	D86N	0	.	.	256	258	GAC	579	581	GAC	193;192;193	G;A;C	189;189;192	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4320	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2999	142.4	1	SNP	p	R87I	0	.	.	259	261	CGT	582	584	CGT	191;197;197	C;G;T	189;190;190	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4320	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2999	142.4	1	SNP	p	S87R	1	.	.	259	261	CGT	582	584	CGT	191;197;197	C;G;T	189;190;190	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4320	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2999	142.4	1	SNP	p	R87W	0	.	.	259	261	CGT	582	584	CGT	191;197;197	C;G;T	189;190;190	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4320	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2999	142.4	1	SNP	p	S88P	0	.	.	262	264	TCC	585	587	TCC	199;200;200	T;C;C	193;197;198	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3742	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2703	137.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1576	1578	GGC	192;186;186	G;G;C	186;183;183	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1255	1257	GCA	190;190;191	G;C,A,G;A	182;180,1,1;186	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1258	1260	ATC	190;194;197	A;T;C	186;187;191	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1270	1272	GTG	188;188;192	G;T;G	184;184;190	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1270	1272	GTG	188;188;192	G;T;G	184;184;190	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1774	1776	ACC	160;162;159	A;C;C	153;161;157	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1828	1830	GCG	134;134;134	G;C,G;G	127;114,1;128	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1828	1830	GCG	134;134;134	G;C,G;G	127;114,1;128	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1951	1953	AGC	141;140;138	A;G;C	130;134;131	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1960	1962	GGC	136;134;133	G;G;C	130;127;124	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3580	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2390	148.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1978	1980	CCG	90;96;97	C,G;C;G,C	79,1;86;87,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5104	ponA	2397	2397	99.92	ponA.l6.c30.ctg.1	3079	164.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2044	porA	1146	1146	99.83	porA.l6.c17.ctg.1	1866	108.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	552	552	C	137	C	122	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2386	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1492	158.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	414	416	GAA	166;166;165	G;A;A	162;162;163	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2386	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1492	158.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	825	827	TCA	186;186;190	T;C;A	182;179;186	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2386	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1492	158.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	954	956	GTC	194;194;193	G,A;T;C	185,1;188;185	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2386	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1492	158.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	966	968	TCT	188;190;190	T;C,T;T	181;185,1;185	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2386	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1492	158.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1284	1286	GCA	177;176;176	G;C;A	176;175;175	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2386	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1492	158.2	1	SNP	p	G120K	1	.	.	358	360	AAG	660	662	AAG	197;197;197	A;A;G	194;195;189	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2386	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1492	158.2	1	SNP	p	A121D	1	.	.	361	363	GAC	663	665	GAC	198;198;198	G;A;C	195;193;195	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2386	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1492	158.2	1	SNP	p	D121N	0	.	.	361	363	GAC	663	665	GAC	198;198;198	G;A;C	195;193;195	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8456	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4814	174.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	938	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	974	95.4	1	SNP	p	V57M	1	.	.	169	171	ATG	487	489	ATG	189;191;194	A;T;G	186;186;189	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
